Ocular Therapeutix, Inc. — FY2021 Form 10-K
Reporting period: Fiscal year ended December 31, 2021. This is an annual report, not a standalone fourth-quarter filing. The company develops and commercializes ophthalmic therapies using a bioresorbable hydrogel platform.
Financial performance and position
| Metric | FY2021 | FY2020 | Change / context |
|---|---|---|---|
| Net product revenue | $43.5 million | $17.4 million | Up $26.1 million, or about 150%; primarily DEXTENZA growth |
| DEXTENZA revenue | $42.0 million | $15.7 million | Primary source of product revenue |
| ReSure Sealant revenue | $1.5 million | $1.7 million | Manufacturing suspended in Q4 2021; no meaningful future revenue expected |
| Cost of product revenue | $4.4 million | $2.1 million | Implied gross margin was approximately 89.9% in 2021, versus 88.0% in 2020 |
| Research and development | $50.1 million | $28.7 million | Higher clinical-trial and personnel costs |
| Selling and marketing | $35.2 million | $26.6 million | Expanded DEXTENZA commercialization effort |
| General and administrative | $31.9 million | $22.9 million | Higher personnel and professional fees, including legal costs |
| Operating loss | $78.0 million | $62.8 million | Loss widened as operating expenses grew |
| Net loss | $6.6 million | $155.6 million | 2021 included a $78.1 million noncash derivative fair-value gain; 2020 included an $86.2 million noncash loss |
| Operating cash flow | $(65.6) million | $(53.6) million | Cash use increased |
| Cash and cash equivalents at year-end | $164.2 million | $228.1 million | Down $63.9 million |
Basic loss per share was $0.09 in 2021 compared with $2.56 in 2020. The filing reports diluted loss per share of $0.98 in 2021, reflecting the assumed conversion of the notes and related derivative accounting; investors should distinguish this non-comparable diluted figure from basic loss per share.
At December 31, 2021, total assets were $204.9 million, total liabilities $116.9 million, and stockholders’ equity $88.0 million. Debt included $25.0 million under the credit facility and $37.5 million principal of convertible notes, plus $6.5 million of accrued interest. The credit facility is interest-only through April 2024, with principal payments thereafter and a stated maturity in November 2025, subject to a possible extension. The convertible notes mature in March 2026.
Management said existing cash was expected to fund planned operations, debt service and capital spending through 2023, subject to assumptions including DEXTENZA sales, clinical-development spending and COVID-19 impacts. The financial-statement note also says cash and the current operating plan support at least the next 12 months; investors should note the different stated horizons.
Material developments and operating outlook
- DEXTENZA revenue increased substantially year over year. Q4 2021 in-market unit sales exceeded 29,000 billable units, up approximately 17% sequentially. Gross-to-net provisions rose to 25.5% of gross DEXTENZA sales from 22.4%, principally reflecting the purchase-volume rebate program.
- The FDA approved DEXTENZA for ocular itching associated with allergic conjunctivitis in October 2021; U.S. commercial launch was planned for Q1 2022. The company planned to add dedicated office-based sales and reimbursement staff.
- OTX-TKI was in Phase 1 trials in Australia and the United States for wet AMD. The U.S. trial was fully enrolled; interim six-month data was expected in the second half of 2022. Australian interim results discussed in February 2022 were preliminary, and the filing described further development as dependent on results.
- OTX-TIC entered a U.S. Phase 2 trial in Q4 2021 for glaucoma or ocular hypertension, with first dosing expected in Q1 2022. Phase 1 interim results presented in February 2022 suggested sustained pressure reduction, but were early-stage data.
- OTX-CSI Phase 2 results did not show separation from vehicle on the primary tear-production endpoint. The company was assessing retention and formulation work before determining next steps. OTX-DED Phase 2 met its prespecified primary endpoint for conjunctival hyperemia, but the trial was not powered for statistical significance; further development plans remained under evaluation.
- AffaMed holds specified Asian-market rights to DEXTENZA and OTX-TIC. Ocular Therapeutix received a $1 million milestone in Q4 2021 and expected a further $2 million clinical-support payment in Q1 2022. Up to $91 million in aggregate milestones and support payments and tiered royalties are possible, but milestone achievement is uncertain. No material collaboration revenue had been recognized by year-end.
- Regeneron terminated its collaboration in August 2021. Ocular Therapeutix lost eligibility for potential development, milestone and royalty payments, but was also relieved of certain potential development-cost reimbursement obligations.
- Management expected research and development spending to remain elevated in 2022 and selling and marketing spending to increase as DEXTENZA commercialization expanded. It cautioned that elective-surgery declines, COVID-19, reimbursement and execution could affect sales and cash needs.
Risks, contingencies and unusual items
- The company has a $545.8 million accumulated deficit, recurring operating losses and negative operating cash flow, and expects further losses. Additional financing may be needed; the $100 million at-the-market program had no sales through February 2022.
- 2021’s comparatively small reported net loss was driven by a large noncash derivative fair-value gain, not operating profitability. The derivative liability was $20.2 million at year-end and is subject to significant valuation assumptions; the auditor identified its valuation as a critical audit matter.
- DEXTENZA sales rely substantially on separate reimbursement. CMS indicated separate payment in ASC and HOPD settings through 2022 and ASC eligibility beyond 2022 under a non-opioid pain-management provision, but future policy could change. The insertion procedure’s 2022 reimbursement was set at $31.58 in ASCs/HOPDs and $37.29 in physicians’ offices, below prior procedure reimbursement levels.
- COVID-19 affected elective ophthalmic procedures, DEXTENZA sales and clinical-trial enrollment. The company also cited supply-chain and staffing uncertainty.
- Manufacturing is concentrated at a single Bedford, Massachusetts facility; some materials, including PEG, are single-sourced, and there are no long-term raw-material supply agreements. ReSure production was suspended to prioritize DEXTENZA.
- Competition includes established branded and generic therapies and other sustained-release programs. The company also faces clinical, regulatory, reimbursement, patent, commercialization and product-liability risks.
- No material legal proceedings were reported. Management and the independent auditor concluded that internal control over financial reporting was effective as of December 31, 2021; the auditor issued an unqualified opinion on the financial statements and controls.
Important facts for investors to verify
- Whether DEXTENZA’s unit growth translates into durable net revenue and whether CMS and other payors maintain adequate separate product and procedure reimbursement.
- How the 2022 allergic-conjunctivitis launch performs, including office adoption, coverage, gross-to-net deductions and incremental selling costs.
- Cash burn, cash runway and financing needs against management’s through-2023 estimate, particularly if sales, trial timing or costs differ from plan.
- Clinical updates for OTX-TKI and OTX-TIC, and the company’s eventual development decisions for OTX-CSI and OTX-DED.
- Debt service terms, the convertible-note conversion and derivative valuation assumptions, and the potential for dilution or refinancing needs.
- Manufacturing capacity and supply continuity, and the extent to which the suspended ReSure business affects future revenue.